Skip to main content
SpringerLink
Log in

Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera

Single center experience and review of literature

  • Original Article
  • Published:
Annals of Hematology Aims and scope Submit manuscript

Abstract

A minor fraction of patients with polycythemia vera (PV) develop a terminal acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS). Analysis of the cytogenetic abnormalities during AML or MDS may help in understanding if this development is part of the natural course of the disease or induced by myelosuppressive therapy. Thirty-six cases with AML or MDS post PV, collected in a single Swedish institution during a 33-year period, are described with special regard to time to development of AML or MDS, therapy given during active PV, and cytogenetic findings during AML or MDS. A further 118 cases of AML or MDS post PV, in whom type of therapy during active PV and cytogenetic findings during AML or MDS were reported, were collected from the literature. AML or MDS developed in our own series after 1–30 years with a fairly constant rate (two cases per year). The most frequent cytogenetic abnormalities were +1q, −5, 5q−, −7, 7q−, +8, +9, 11q−, 13q−, and 20q−. When patients in the total material (n = 154) were divided with regard to treatment during active PV, marked differences were observed. The highest frequency of abnormalities was found in patients given multiple lines of therapy (n = 61), dominating features being −5/5q− in 28 patients (46%), −7/7q− in 19 patients (31%), numerous translocations in 24 patients (39%), and unidentified markers in 22 patients (36%). Half of the patients treated with hydroxyurea alone showed a −5 or 5q− abnormality. In patients treated with phlebotomy alone, +8 and +9 were the most frequent findings. The type of therapy given during active PV influences the type of chromosome abnormalities present during terminal AML or MDS and can also be instrumental in the development of leukemia.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1

Similar content being viewed by others

References

  1. Andersen MK, Pedersen-Bjergaard J (2000) Increased frequency of dicentric chromosomes in therapy-related MDS and AML compared to de novo disease is significantly related to previous treatment with alkylating agents and suggest a specific susceptibility to chromosome breakage at the centromere. Leukemia 14:105–111

    Article  PubMed  CAS  Google Scholar 

  2. Andrieux J, Demory JL, Caulier MT, Agape P, Wetterwald M, Bauters F, Lai JL (2003) Karyotypic abnormalities in myelofibrosis following polycythemia vera. Cancer Genet Cytogenet 140:118–123

    Article  PubMed  CAS  Google Scholar 

  3. Barbui T (2004) The leukemia controversy in myeloproliferative disorders: is it a natural progression of disease, a secondary sequel of therapy, or a combination of both. Semin Hematol 4:15–17

    Article  Google Scholar 

  4. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1982) Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 51:181–199

    Google Scholar 

  5. Bennett JM, Catovsky D, Daniel MT, Flandrin G, Galton DA, Gralnick HR, Sultan C (1985) Proposed revised criteria for the classification of acute myeloid leukaemia. A report of the French–American–British Cooperative Group. Ann Intern Med 103:620–625

    PubMed  CAS  Google Scholar 

  6. Berger R, Bernheim A, Flandrin G, Dresch C, Najéan Y (1984) Cytogenetic studies on acute non-lymphocytic leukemias following polycythemia vera. Cancer Genet Cytogenet 1:441–451

    Article  Google Scholar 

  7. Berk PD, Goldberg JD, Silverstein MN, Weinfeld A, Donovan PB, Ellis JT, Landaw SA, Laszlo J, Najean Y, Pisciotta AV, Wasserman LR (1981) Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304:441–447

    Article  PubMed  CAS  Google Scholar 

  8. Berlin NI (1975) Diagnosis and classification of the polycythemias. Semin Hematol 12:339–351

    PubMed  CAS  Google Scholar 

  9. Bram S, Swolin B, Rödjer S, Stockelberg D, Ögärd I, Bäck H (2003) Is monosomy 5 an uncommon aberration? Fluorescence in situ hybridisation reveals translocations and deletions in myelodysplastic syndromes or acute myelocytic leukaemia. Cancer Genet Cytogenet 142:107–114

    Article  PubMed  CAS  Google Scholar 

  10. National Board of Health and Welfare (2005) Cancer Incidence in Sweden 2005. http://www.socialstyrelsen.se/NR/rdonlyres/FD7B695E-A55F-41F4-B539-4C63D8199601/7192/2007423.pdf. Accessed 13 June 2007

  11. Cervantes F, Tassies D, Salgado C, Rovira M, Pereira A, Rozman C (1991) Acute transformation in nonleukemic chronic myeloproliferative disorders: actuarial probability and main characteristics in a series of 218 patients. Acta Haematol 85:124–127

    Article  PubMed  CAS  Google Scholar 

  12. Chim CS, Ma SK (2005) Eosinophilic leukemic transformation in polycythemia rubra vera(PRV). Leuk Lymphoma 46:447–450

    Article  PubMed  CAS  Google Scholar 

  13. Dastugue N, Pris J, Colombies P (1990) Translocation t(3;21)(q26;q22) in acute myeloblastic leukaemia secondary to polycythemia vera. Cancer Genet Cytogenet 44:275–276

    Article  PubMed  CAS  Google Scholar 

  14. Diez-Martin JL, Graham DL, Petitt RM, Dewald GW (1991) Chromosome studies in 104 patients with polycythemia vera. Mayo Clin Proc 66:287–299

    PubMed  CAS  Google Scholar 

  15. Finazzi G, Caruso V, Marchioli R, Capnist G, Chisesi T, Finelli C, Gugliotta L, Landolfi R, Kutti J, Gisslinger H, Marilus R, Patrono C, Pogliani EM, Randi ML, Villegas A, Tognoni G, Barbui T, ECLAP Investigators (2005) Acute leukaemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study. Blood 105:2664–2670

    Article  PubMed  CAS  Google Scholar 

  16. Fruchtman SM (2004) Treatment paradigms in the management of myeloproliferative disorders. Semin Hematol 4(suppl 3):18–22

    Article  CAS  Google Scholar 

  17. Groupe Francais de Cytogénétique Hématologique (1988) Cytogenetics of acutely transformed chronic myeloproliferative syndromes without a Philadelphia chromosome A multicenter study of 55 patients. Cancer Genet Cytogenet 32:157–168

    Article  Google Scholar 

  18. Halsey C, Roberts IA (2003) The role of hydroxyurea in sickle cell disease. Br J Haematol 120:177–186

    Article  PubMed  CAS  Google Scholar 

  19. Herry A, Douet-Guilbert N, Morel F, Le Bris MJ, De Braekeleer M (2007) Redefining monosomy 5 by molecular cytogenetics in 23 patients with MDS/ AML. Eur J Haematol 78:457–467

    Article  PubMed  Google Scholar 

  20. Higuchi T, Okada S, Mori H, Niikura H, Omine M, Terada H (1995) Leukemic transformation of polycythemia vera and essential thrombocythemia possibly associated with an alkylating agent. Cancer 75:471–477

    Article  PubMed  CAS  Google Scholar 

  21. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization Classification of tumours. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. IARC, Lyon

    Google Scholar 

  22. Johansson P, Kutti J, Andreasson B, Safai-Kutti S, Vilen L, Wedel H, Ridell B (2004) Trends in the incidence of Chronic Philadelphia chromosome negative(Ph-) myeloproliferative disorders in the city of Göteborg, Sweden, during 1983–99. J Intern Med 256:161–165

    Article  PubMed  CAS  Google Scholar 

  23. Kiladjian JJ, Rain JD, Bernard JF, Briere J, Chomienne C, Fenaux P (2006) Long-term incidence of haematological evolution in three French prospective studies of hydroxyurea and pipobroman in polycythemia vera and essential thrombocythemia. Semin Thromb Hemost 32:417–421

    Article  PubMed  CAS  Google Scholar 

  24. Kurosawa M, Iwasaki H (2002) Megakaryoblastic transformation of polycythemia vera with hypercalcemia. Ann Hematol 81:668–671

    Article  PubMed  CAS  Google Scholar 

  25. Landaw SA (1986) Acute leukemia in polycythemia vera. Semin Hematol 23:156–65

    PubMed  CAS  Google Scholar 

  26. Landaw SA (1995) Acute leukemia in polycythemia vera. In: Wasserman LR, Berk PD (eds) Polycythaemia vera and the myeloproliferative disorders. Saunders, Philadelphia, pp 154–165

    Google Scholar 

  27. Le Beau MM, Westbrook CA, Diaz MO, Larson RA, Rowley JD, Gasson JC, Golde DW, Sherr CJ (1986) Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. J Clin Oncol 4:325–345

    PubMed  Google Scholar 

  28. Merlat A, Lai JL, Sterkers Y et al (1999) Therapy-related myelodysplastic syndrome and acute myeloid leukaemia with 17p deletion. A report on 25 cases. Leukemia 13:250–257

    Article  PubMed  CAS  Google Scholar 

  29. Mertens F, Johansson B, Heim S, Kristoffersson U, Mitelman F (1991) Karyotypic patterns in chronic myeloproliferative disorders. Report on 74 cases and review of the literature. Leukemia 5:214–220

    PubMed  CAS  Google Scholar 

  30. Modan B, Lilienfeld AM (1965) Polycythemia vera and leukemia—the role of radiation treatment: a study of 1222 patients. Medicine 44:305–44

    Article  PubMed  CAS  Google Scholar 

  31. Nand S, Messmore H, Fisher SG, Bird ML, Schultz W, Fisher RI (1990) Leukemic transformation in polycythemia vera. Am J Hematol 34:32–36

    Article  PubMed  CAS  Google Scholar 

  32. Nielsen I, Hasselbalch HC (2003) Acute leukaemia and myelodysplasia in patients with Philadelphia chromosome negative chronic myeloproliferative disorder treated with hydroxyurea alone or with hydroxyurea after busulphan. Am J Hematol 74:26–31

    Article  PubMed  CAS  Google Scholar 

  33. Ohyashiki K, Nagasu M, Hojo H, Iwabuchi A, Ohyashiki JH, Toyama K (1989) Myelodysplastic syndrome with trisomy 11 associated with polycythemia vera. Am J Hematol 3:122–125

    Article  Google Scholar 

  34. Passamonti F, Rumi E, Arcaini L, Castagnola C, Lunghi M, Bernasconi P, Della Porta MG, Columbo N, Pascutto C, Cazzola M, Lazzarino M (2005) Leukemic transformation of polycythemia vera. Cancer 104:1032–1036

    Article  PubMed  Google Scholar 

  35. Passamonti F, Malabarba L, Orlandi E, Barate C, Canevari A, Brusamolino E, Bonfichi M, Arcaini L, Caberlon S, Pascutto C, Lazzarino M (2003) Polycythemia vera in young patients: a study on the long-term risks of thrombosis, myelofibrosis and leukemia. Hematologica 88:13–18

    Google Scholar 

  36. Pedersen-Bjergaard J, Pedersen M, Roulston D, Philip P (1995) Different genetic pathways in leukemogenesis for patients presenting with therapy-related myelodysplasia and therapy-related acute myeloid leukaemia. Blood 86:3542–3552

    PubMed  CAS  Google Scholar 

  37. Pierre RV, Whang-Peng J (1995) Cytogenetics. In: Wasserman LR, Berk PD (eds) Polycythaemia vera and the myeloproliferative disorders. Philadelphia, Saunders, pp 91–101

    Google Scholar 

  38. Rege-Cambrin G, Mecucci C, Tricot G, Michaux JL, Louwagie A, Van Hove W, Francart H, Van den Berghe H (1987) A chromosomal profile of polycythemia vera. Cancer Genet Cytogenet 25:233–245

    Article  PubMed  CAS  Google Scholar 

  39. Rege-Cambrin G, Speleman F, Kerim S, Scaravaglio P, Carozzi F, Dal Cin P, Michaux JL, Offner F, Saglio G, Van den Berghe H (1991) Extra translocation +der(1q9p) is a prognostic indicator in myeloproliferative disorders. Leukemia 12:1059–1063

    Google Scholar 

  40. Rowley JD (1975) Abnormalities of chromosome 1 in myeloproliferative disorders. Cancer 36:1748–1757

    Article  PubMed  CAS  Google Scholar 

  41. Shaffer LG, Tommerup N (2005) An International System for Human Cytogenetic Nomenclature (ISCN). Karger, Basel

    Google Scholar 

  42. Shamdas GJ, Spier CM, List AF (1991) Myelodysplastic transformation of polycythemia vera: Case report and review of the literature. Am J Hemat 37:45–48

    Article  PubMed  CAS  Google Scholar 

  43. Slovak ML, Kopecky KJ, Cassileth PA, Harrington DH, Theil KS, Mohamed A, Paietta E, Willman CL, Head DR, Rowe JM, Forman SJ, Appelbaum FR (2000) Karyotypic analysis predicts outcome of preremission and postremission therapy in adult myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood 96:4075–4083

    PubMed  CAS  Google Scholar 

  44. Swolin B, Weinfeld A, Westin J (1986) Trisomy 1q in polycythemia vera and its relation to disease transition. Am J Hemat 22:155–167

    Article  PubMed  CAS  Google Scholar 

  45. Swolin B, Weinfeld A, Westin J (1988) A prospective long-term cytogenetic study in polycythemia vera in relation to treatment and clinical course. Blood 72:386–395

    PubMed  CAS  Google Scholar 

  46. Tefferi A (2000) Myelofibrosis with myeloid metaplasia. N Engl J Med 342:1255–65

    Article  PubMed  CAS  Google Scholar 

  47. Testa JR, Kanofsky JR, Rowley JD, Baron JM, Vardiman JW (1981) Karyotypic patterns and their clinical significance in polycythemia vera. Am J Hematol 1:29–45

    Article  Google Scholar 

  48. Tothova E, Fricova M, Stecova N, Hlebaskova M, Kafkova A, Raffac S, Guman T, Svorcova E, Nebesnakova E (2001) Leukemic transformation of polycythemia vera after treatment with hydroxyurea with abnormalities of chromosome 17. Neoplasma 48:389–392

    PubMed  CAS  Google Scholar 

  49. Van den Berghe H, Broeckert-van Orshoven A, Louwagie A, Verwilghen R, Michaux J-L, Sokal G (1979) Transformation of polycythemia vera to myelofibrosis and late appearance of a 5q-chromosome anomaly. Cancer Genet Cytogenet 1:157–167

    Article  Google Scholar 

  50. Weinfeld A, Westin J, Ridell B, Swolin B (1977) Polycythemia vera terminating in acute leukemia. A clinical, cytogenetic, and morphologic study in eight patients treated with alkylating agents. Scand J Haematol 19:255–272

    Article  PubMed  CAS  Google Scholar 

  51. Weinfeld A, Swolin B, Westin J (1994) Acute leukaemia after hydroxyurea therapy in polycythemia vera and allied disorder: prospective study of efficacy and leukaemogenicity with therapeutic implications. Eur J Haematol 52:134–139

    Article  PubMed  CAS  Google Scholar 

  52. Westin J, Wahlström J, Swolin B (1976) Chromosome studies in untreated polycythemia vera. Scand J Haematol 17:183–196

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The study was supported by the Swedish Cancer Society (grant no. 3321-B95-04XAA). We thank Professor Anders Odén for statistical advice.

Author information

Authors and Affiliations

  1. Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital, 413 45, Göteborg, Sweden

    Birgitta Swolin

  2. Section of Hematology, Department of Medicine, Sahlgrenska University Hospital, 413 45, Göteborg, Sweden

    Stig Rödjer & Jan Westin

Authors
  1. Birgitta Swolin
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Stig Rödjer
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jan Westin
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jan Westin.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Swolin, B., Rödjer, S. & Westin, J. Therapy-related patterns of cytogenetic abnormalities in acute myeloid leukemia and myelodysplastic syndrome post polycythemia vera. Ann Hematol 87, 467–474 (2008). https://doi.org/10.1007/s00277-008-0461-4

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00277-008-0461-4

Keywords

Search

Navigation